Canadian rheumatology group says no evidence supports medical cannabis for joint diseases but offers pragmatic guidance | Research

The takeaway

The Canadian Rheumatology Association found no clinical trials and insufficient evidence for medical cannabis in rheumatic diseases, but issued pragmatic guidance to help physicians have informed conversations with patients who use it anyway.

People with arthritis, fibromyalgia, or other rheumatic conditions considering cannabis, and those interested in the evidence gap for cannabis in pain management.

Zero clinical trials of medical cannabis for any rheumatic disease

What the researchers found

No clinical trials of medical cannabis in rheumatology patients existed at the time of review. Evidence is insufficient for benefit in fibromyalgia, osteoarthritis, rheumatoid arthritis, and back pain, but there is evidence of a high risk of harm. Short-term psychomotor effects are expected; long-term risks are unknown.

Why it matters

With cannabis legalized in Canada, rheumatology patients are increasingly using it for pain and inflammation. This position statement addresses a practical reality: patients are using cannabis regardless of evidence gaps, so clinicians need guidance on harm reduction.

The numbers in context

Zero clinical trials of medical cannabis in rheumatology patients. Evidence insufficient for fibromyalgia, osteoarthritis, rheumatoid arthritis, and back pain. High risk of harm documented. Short-term psychomotor risks anticipated.

How the study worked

Literature review by the Canadian Rheumatology Association Therapeutics Committee, assessing available evidence on medical cannabis for rheumatic conditions and developing a pragmatic position statement approved by the CRA board.

What this study cannot tell us

Position statement rather than systematic review. Based on absence of evidence rather than evidence of absence. Extrapolates from non-rheumatology cannabis research. Does not differentiate between cannabis products, doses, or routes.

How to read the evidence

Moderate: official position statement from a national medical association, though based on absence of direct evidence.

When this study was published

Published in 2019.

The bigger picture

The gap between patient interest and clinical evidence for cannabis in rheumatic diseases is striking. Zero clinical trials exist despite high patient demand. This highlights a broader pattern where cannabis legalization outpaces the research needed to guide medical use.

Questions still open

Why have no clinical trials been conducted for cannabis in rheumatic diseases despite high patient interest? Could specific cannabinoids like CBD offer anti-inflammatory benefits with acceptable risk profiles? What does harm reduction look like for rheumatology patients who choose to use cannabis?

Common questions

Does medical cannabis help arthritis?

As of this 2019 position statement, there were no clinical trials of medical cannabis in any rheumatic disease including arthritis. The Canadian Rheumatology Association found insufficient evidence for benefit but evidence of harm risk.

Should people with rheumatic diseases avoid cannabis?

The CRA acknowledges that many patients use cannabis and emphasizes harm reduction rather than blanket prohibition. They encourage open dialogue between patients and doctors to ensure safety, while noting the evidence gap.

Read the original research

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

The Journal of rheumatology, 46(5), 532-538

View on PubMed ↗Publisher’s paper ↗

Citation

Fitzcharles, Mary-Ann; Niaki, Omid Zahedi; Hauser, Winfried; Hazlewood, Glen. (2019). Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.. The Journal of rheumatology, 46(5), 532-538. https://doi.org/10.3899/jrheum.181120